Plus Therapeutics to Implement 1-for-25 Reverse Stock Split to Comply with Nasdaq Listing Requirements

Plus Therapeutics announced a 1-for-25 reverse stock split to ensure compliance with Nasdaq's $1 minimum bid price requirement. The split will reduce outstanding shares from approximately 171.55 million to 6.86 million and become effective on April 2, 2026. Holders of fractional shares will receive cash payments in lieu of fractional shares, and equity awards and warrants will be adjusted accordingly.